For chemotherapy, we found our risk score significantly associated with the methylation status of the MGMT promoter, which can effectively predict the responsiveness of glioma to alkylating agents, the commonly used chemotherapeutic drugs for glioma (Esteller et al., 2000; Hegi et al., 2005; Song et al., 2015). Here, MGMT is linked to central nervous system cancer.